A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

Cassava will stop developing simufilam for Alzheimer’s this year after a Phase 3 trial failed to improve cognition and daily function.

Age at menopause may interact with factors related to the health of synapses, or nerve cell connections, to influence the risk of Alzheimer’s disease in women, a study found. Associations between ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Winter in a cold climate can add challenges when caregiving for someone with dementia, columnist Ray Burow writes.

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease.

Buntanetap, a small molecule from Annovis Bio, improved cognitive function in people with mild Alzheimer’s with certain biomarkers.

Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.

The PrecivityAD blood test was found to influence doctors' decisions to treat for Alzheimer's disease in a real-world study.

Quest Diagnostics has launched a consumer-initiated blood test for adults in the U.S. that assesses Alzheimer’s disease risk by measuring levels of certain forms of the amyloid beta protein, a known ...

On-demand treatment with BXCL501 was found to significantly ease episodes of agitation for Alzheimer's patients in a Phase 3 clinical trial.

"Encouraging results" were reported in eight Alzheimer’s patients with dementia who were treated with the experimental therapy COYA 301.